Potential new therapeutic options in Behçet's syndrome

BioDrugs

Volumn 15, Issue 1, 2001, Pages 25-35

  Russell, Andrew I ^a   Lawson, Wendy A ^b   Haskard, Dorian O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTIINFECTIVE AGENT; AZAPROPAZONE; AZATHIOPRINE; BENZATHINE PENICILLIN; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; INDOMETACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; ORABASE; SUCRALFATE; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG;

ARTHRITIS; BEHCET DISEASE; BLOOD CLOTTING; CYTOKINE PRODUCTION; DRUG RESPONSE; EYE INFLAMMATION; FIBRINOLYSIS; GENETIC SUSCEPTIBILITY; GENITAL ULCER; HUMAN; INFECTION; INFLAMMATION; LYMPHOCYTE; MONOCYTE; MOUTH ULCER; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE INJURY;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; HUMANS; RECOMBINANT PROTEINS; STEROIDS;

EID: 0035112198     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115010-00003     Document Type: Review

References (79)

1. Behçet H, Über rezidivierende. aphthöse. durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937: 36: 1152-7
2. Kaklamani VG, Vaiopoulos G. Kaklamanis PG. Behcefs disease. Seinin Arthritis Rheum 1998: 27: 197-217
3. Sakaiie T, Takeno M. Suzuki N. et ul. Behçet's discase. N Engl J Med 1999:341: 1284-91
4. Yazici H, Yurdakul S, Hamuryudan V. Behçet's syndrome. Curr Opin Rheumatol 1999; 11: 53-7
5. International Study Group for Behçet's Disease, Criteria for diagnosis of Behçet's disease. Lancet 1990:335: 1078-80
6. Shimizu T, Ehrlich GE. Inaha G, et al. Behçel disease (Behçet syndrome). Seinin Arthritis Rheum 1979: 8: 223-60
7. Yurdakul S, Günaydin I, Tüzün Y. et al. The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol 1988; 15: 820-2
8. Pickering MC, Haskard DO, Behçet's syndrome - a review of 230 referrals. J R Coll Physicians Lond 2000: 34: 169-77
9. Zouboulis CC, Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne (Paris) 1999; 150: 488-98
10. Curler A, Boy vat A, Tursen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J 1997:38:423-7
11. Turan B, Gallati H. Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997:24: 128-32
12. Yazici H, Baaran G, Hamuryudan V. et al. The ten-year mortality in Behçet's syndrome. BrJ Rheumatol 1996:35:139-41
13. Benezra D, Cohen E, Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986; 70: 589-92
14. Ando K, Fujino Y. Izawa Y. et al. Epidemiological features and visual prognosis of Behçet's disease. Jap J Ophthalmol 2000: 43:312-7
15. OhnoS, AsanumaT, SugiuraS, etal. HLA-Bw51 and Behçet's disease. JAMA 1978: 240: 529 [letter]
16. Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition of Behçet's disease. Int Rev Immunol 1997; 14: 33-48
17. Mizuki N, OtaM. KimuraM.etal.Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions \vith Behçet disease. Proc Nail Acad Sei USA 1997; 94: 1298-303
18. Mizuki N, Ota M, Katsuyama Y. et al. Association analysis between the MIC-Aand HLA-B alleles in Japanese patients with Behçet's disease. Arthritis Rheum 1999:42: 1961-6
19. Cakir N, Yazici H. Chamberlain MA, et al. Response to intradermal injection of monosodium urate crystals in Behçet's syndrome. Ann Rheum Dis 1991; 50: 634-6
20. Mizushima Y, Matsuda T, Hoshi K. et al. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15: 1029-30
21. Eglin RP, Lehner T. Subak-Sharpc JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet 1982; II: 1356-61
22. Earn AG, Siminovitch KA, Carette S, et al. Neonatal Behçet's syndrome in an infant of a mother with the disease. Ann Rheum Dis 1981:40:509-12
23. Stark AC, Bhakta B. Chamberlain MA. et al. Life-threatening transient neonatal Behçet's disease. BrJ Rheumatol 1997; 36: 700-2
24. Lee KH, Bang D, Choi ES, et al. Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behçet's disease. Arch Dermatol Res 1999: 291: 374-81
25. Trtolo G, Accardo-Palumbo A. Carbone MC, et al. Enhancement of endothelial cell E-selection expression by sera from patients with active Behçet's disease: moderate correlation with anti-endolhelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999: 91: 330-7
26. Lehner T, The rule of heal shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997: 14: 21-32
27. Hasan A, Fortune F, Wilson A, et al. Role of gamma delta T cells in pathogenesis and diagnosis of Behçet's disease. Lancet 1996:347: 789-94
28. Hirohata S, Hashimoto T, Abnormal T cell responses to bacterial superantigens in Behçet's disease (BD). Clin Exp Immunol 1998: 112:317-24
29. Frassanito MA, Dammacco R, Cafforio P, et al. Th I polariJ.ation of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999: 42: 1967-74
30. Yamashita N, Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Int Rev Immunol 1997: 14: 11-9
31. Mege J-L, Dilsen N. Sanguedolce V. et al. Overproduction of monocyte derived tumor necrosis factor a. interleukin (IL) 6, IL-8 and increased neutrophil Superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1S44-9
32. MammoL, al-Dalaan A, BahabriSS.etal. Association of factor V Leiden with Behçet's disease. J Rheumatol 1997; 24: 2196-8
33. Gul A, Ozbek U. Ozturk C, et al. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. BrJ Rheumatol 1996; 35: II78-80
34. Hampton KK, Chamberlain MA, Menon DK, et al. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost 1991:66: 292-4
35. Saenz A, Ausejo M, Shea B, et al. Pharmacolherapy for Behçet's syndrome (Cochrane review). In: TheCochrane Library. Issue 3, 2000. Oxford Update Software
36. Bhakta BB, Brennan P. James TE. et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-33
37. Simsek H, Dundar S. Telatar H. Treatment of Behçet disease with indomethacin. Int J Dermatol 1991: 30: 54-7
38. Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy ofazapropa/one in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995; 13:493-5
39. Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulcération of Behçet's disease. Arch Dermatol 1999: 135: 529-32
40. Ben-Chetrit E, Levy M, Colchicine: 1998 update. Semin Arthritis Rheum 1998:28:48-59
41. Matsumura N, Mizushima Y, Leucocyte movement and colchicine treatment in Behçet's disease |letter|. Lancet 1975; II: 813
42. Mizushima Y, Matsumura N, Mori M. et al. Colchieine in Behçet's disease [letter]. Lancet 1977; II: 1037
43. Aklulga E, Altaç M. Miiftiioglu A, et al. A double blind study of colchicinc in Behçet's disease. Haematologica 1980; 65: 399-402
44. Yurdakul S, Mat C, OJ.yazgan Y. et al. A double blind study of colchicine in Behçet's syndrome (BS) [abstract). Arthritis Rheum 1998:41: S356
45. Sarica K, Suzer O, Ourler A, et al. Urological evaluation of Behçet patients and the effect of colchicine on fertility. Eur Urol 1995; 27: 39-42
46. Calgiineri M, Kiraz S, Ertenli I. et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçei's diseuse: a randomiJ.ed clinical trial. Arthritis Rheum 1996: 39: 2062-5
47. Culguneri M, Ertenli I, Kiraz S, et al, Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996; 192: 125-8
48. Kaneko F, Oyama N. Nishihu A. Steptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997: 38: 444-54
49. Tseng S, Pak G. Washenik K. et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Derniatol 1996; 35: 969-79
50. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome [letter]. Arch Dermatol 1982: 118: 536
51. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomiJ.ed. double-blind, placebo-controlled trial. Ann Intern Med 1998: 128:443-50
52. Powell RJ, Gardner-Mcdwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994: 70: 901-4
53. Gardner-Medwin JM, Smith NJ. Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulcération in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994: 53: 828-32
54. Ya/ici H, Pazarli H, Barnes CG, et al, A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990: 322: 281-5
55. Hamuryudan V, Özyazgan Y. Hizli N. et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997:40: 769-74
56. Kilmartin DJ, Forrester JV. Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998; 352: 35-6
57. Larkin G, Lightman S. Mycophenolate mofetil: a useful inimunosuppressive in inflammatory eye disease. Ophthalmology 1999: 106:370-4
58. Masuda K, Urayama A, Kogure M. et al. Double-masked trial of cyclosporin versuscolchicine and long term open study of cyclosporin in Behçets disease. Lancet 1989: I: 1093-6
59. Kotake S, Higashi K. Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999; 106:586-9
60. Ergun T, Gürbüz C), Yurdakul S. et al. Topical cyclosporin-A for treatment of oral ulcers of Behçet's syndrome. Int J Dermatol 1997:36:717-20
61. Su/uki N, Kaneko S. Ichino M. et al. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçefs disease. Arthritis Rheum 1997: 40: 1157-67
62. Mochizuki M, Masuda K. Sakane T. et al. Amulticenterclinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 1991: 23: 3343-6
63. Sakane T, Mochi/uki M, Inaba G. et al. A phase II study of FK506 (tacrolimus| on refractory uveitis associated with
64. Behçet's disease and allied conditions, Ryumachi 1995; 35: 802-13
65. Slopcr CM, Powell RJ. Dua HS. Tacrolimus (FK506) in the ireatment of posterior uveitis refractory to cyclosporinc. Ophthalmology 1999: 106: 723-8
66. Shah SS, Low, der CY. Schmitl MA. et al. Low-dose nietholrexate therapy for ocular inflammatory disease. Ophthalmology 1992; 99: 1419-23
67. Hirohala S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatrie manifestations in Behcet's disease. JMeurol Sei 1998: 139: 181-5
68. Tessler HH, Jennings T. High-dose short-term chloramhucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990:74:353-7
69. Davatchi F, Baygan F. Chains H. et al. Cyelophosphamide in the treatment of the ocular manifestations of Behcet's disease. J Rheumatol 1984; 11:404-5
70. O'Duffy JD, Robertson DM. Goldstein N P. Chloramhucil in the treatment of uveitis and meningoeneephalitis of Behcet's dis ease. Am J Med 1984: 76: 75-84
71. Özyazgan Y, Yurdakui S. Yazici H. et al. Low dose cyclosporin A versus pulsed Cyelophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992: 76: 241-3
72. Borden EC, Interferons - expanding therapeutic roles. N Engl J Med 1992:326: 1491-3
73. Zouboulis CC, Orfanos CE. Treatment of Adamant iades Behçet disease with systemic Interferon. Arch Dermatol 199: 134: 1010-6
74. Hamuryudan V, Yurdakui S, Rosenkaimer F. et al. Ineffieaey of topical alpha Interferon in the treatment of oral ulcers of Behcet's syndrome: a randomi/ed. double blind trial. Br J Rheumatol 1991:30: 395-6
75. Tsamhaos D, Eichelberg D. Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986: 278: 335-6
76. Antonelli G, Current! M. Turri/iani O. et al. Neutralising antibodies to interfcron-alpha: relative frequency in patients treated with different Interferon preparations. J Infect Dis 1991; 163: 882-5
77. Guyer DR, Tiedeman J. Yannuzzi LA. et al. Imerferon-associated rctinopathy. Arch Ophthalmol 1993: 111: 350-6
78. Segawa F, Shimizu Y, Saito E, et al. Behcet's disease induced by interferon therapy for chronic myelogenous leukemia. J Rheumatol 1995:22: 1183-4
79. Budak-Alpdogan T, Demireay Z. Alpdogan O. et al. Behcet's disease in patients with chronic myelogenous leukemia: possible role of intcrferon-alpha treatment in the occurrence of Behest's symptoms. Ann Hematol 1997: 74: 45-8